The GLP-1 Products and Players - Expanding a new Era of Pharmaceutical Products for Diabetes and Weight Loss
Investorideas.com reports on the expanding global GLP-1 receptor agonist market, highlighting Integrated Ventures, Inc. (OTCQB: INTV) as a new player. The market is growing at a CAGR of 21.65% from 2024 to 2030, driven by strong product pipelines and formulation advancements. INTV announced its entry into the health and wellness sector through its subsidiary MedWell USA, , focusing on B2B procurement for pharmaceutical products, particularly in medical weight loss and GLP-1 markets.
The GLP-1 market for obesity and diabetes is forecasted to reach $129 billion by 2029, with 40 million users and a 30% CAGR. Other companies like Hims & Hers Health and Viking Therapeutics are also making strides in the GLP-1 and weight loss markets. The sector's future looks promising, with companies expanding geographically and seeking approvals for additional indications like obesity and cardiovascular events.
Investorideas.com riporta sull'espansione del mercato globale degli agonisti del recettore GLP-1, evidenziando Integrated Ventures, Inc. (OTCQB: INTV) come un nuovo attore. Il mercato sta crescendo a un CAGR del 21,65% dal 2024 al 2030, guidato da forti pipeline di prodotto e progressi nelle formulazioni. INTV ha annunciato il suo ingresso nel settore della salute e del benessere tramite la sua filiale MedWell USA, concentrandosi sull'approvvigionamento B2B per prodotti farmaceutici, in particolare nei mercati della perdita di peso medica e GLP-1.
Si prevede che il mercato GLP-1 per obesità e diabete raggiunga $129 miliardi entro il 2029, con 40 milioni di utenti e un CAGR del 30%. Altre aziende come Hims & Hers Health e Viking Therapeutics stanno facendo progressi anche nei mercati GLP-1 e perdita di peso. Il futuro del settore appare promettente, con le aziende che si espandono geograficamente e cercano approvazioni per ulteriori indicazioni come obesità ed eventi cardiovascolari.
Investorideas.com informa sobre la expansión del mercado global de agonistas del receptor GLP-1, destacando a Integrated Ventures, Inc. (OTCQB: INTV) como un nuevo jugador. El mercado está creciendo a una TCCA del 21,65% de 2024 a 2030, impulsado por sólidas carteras de productos y avances en formulaciones. INTV anunció su entrada en el sector de la salud y el bienestar a través de su subsidiaria MedWell USA, enfocándose en la adquisición B2B de productos farmacéuticos, particularmente en los mercados de pérdida de peso médica y GLP-1.
Se prevé que el mercado de GLP-1 para la obesidad y la diabetes alcance $129 mil millones para 2029, con 40 millones de usuarios y una TCCA del 30%. Otras empresas como Hims & Hers Health y Viking Therapeutics también están avanzando en los mercados de GLP-1 y pérdida de peso. El futuro del sector parece prometedor, con empresas que se expanden geográficamente y buscan aprobaciones para indicaciones adicionales como la obesidad y eventos cardiovasculares.
Investorideas.com은 GLP-1 수용체 작용제의 세계 시장 확장을 보도하며 Integrated Ventures, Inc. (OTCQB: INTV)를 새로운 플레이어로 강조합니다. 이 시장은 2024년부터 2030년까지 21.65%의 CAGR로 성장하고 있으며, 강력한 제품 파이프라인과 포뮬레이션 발전에 힘입고 있습니다. INTV는 자회사 MedWell USA를 통해 건강 및 웰빙 부문에 진출했으며, 특히 의료 체중 감량 및 GLP-1 시장에서의 의약품 B2B 조달에 집중하고 있습니다.
비만 및 당뇨병을 위한 GLP-1 시장은 2029년까지 $1290억에 이를 것으로 예상되며, 4천만 명의 사용자와 30%의 CAGR을 기록할 것입니다. Hims & Hers Health와 Viking Therapeutics와 같은 다른 기업들도 GLP-1 및 체중 감량 시장에서 성과를 내고 있습니다. 이 분야의 미래는 유망하며, 기업들은 지리적으로 확장하고 비만 및 심혈관 사건과 같은 추가 적응증에 대한 승인을 추구하고 있습니다.
Investorideas.com rapporte sur l'expansion du marché mondial des agonistes du récepteur GLP-1, mettant en avant Integrated Ventures, Inc. (OTCQB: INTV) comme un nouvel acteur. Le marché croît à un TCAC de 21,65% de 2024 à 2030, soutenu par de solides pipelines de produits et des avancées en formulation. INTV a annoncé son entrée dans le secteur de la santé et du bien-être par l'intermédiaire de sa filiale MedWell USA, en se concentrant sur l'approvisionnement B2B pour des produits pharmaceutiques, en particulier dans les marchés de la perte de poids médicale et du GLP-1.
Le marché du GLP-1 pour l'obésité et le diabète devrait atteindre 129 milliards de dollars d'ici 2029, avec 40 millions d'utilisateurs et un TCAC de 30%. D'autres entreprises comme Hims & Hers Health et Viking Therapeutics avancent également dans les marchés du GLP-1 et de la perte de poids. L'avenir du secteur semble prometteur, les entreprises s'étendant géographiquement et cherchant des approbations pour des indications supplémentaires comme l'obésité et les événements cardiovasculaires.
Investorideas.com berichtet über den wachsenden globalen Markt für GLP-1-Rezeptor-Agonisten und hebt Integrated Ventures, Inc. (OTCQB: INTV) als neuen Akteur hervor. Der Markt wächst im Zeitraum von 2024 bis 2030 mit einer CAGR von 21,65%, angetrieben von starken Produktpipelines und Fortschritten in der Formulierung. INTV kündigte seinen Eintritt in den Gesundheits- und Wellness-Sektor durch seine Tochtergesellschaft MedWell USA an und konzentriert sich auf B2B-Beschaffung von pharmazeutischen Produkten, insbesondere in den Märkten für medizinischen Gewichtsverlust und GLP-1.
Der GLP-1-Markt für Fettleibigkeit und Diabetes wird voraussichtlich bis 2029 129 Milliarden US-Dollar erreichen, mit 40 Millionen Nutzern und einer CAGR von 30%. Auch andere Unternehmen wie Hims & Hers Health und Viking Therapeutics machen Fortschritte in den GLP-1- und Gewichtsverlustmärkten. Die Zukunft des Sektors sieht vielversprechend aus, da die Unternehmen geografisch expandieren und Genehmigungen für weitere Indikationen wie Fettleibigkeit und kardiovaskuläre Ereignisse anstreben.
- INTV enters the rapidly growing health and wellness sector, focusing on the booming medical weight loss and GLP-1 markets
- Global GLP-1 receptor agonist market expanding at a CAGR of 21.65% from 2024 to 2030
- GLP-1 market for obesity and diabetes forecasted to reach $129 billion by 2029, with 40 million users and 30% CAGR
- INTV establishing two more subsidiaries to broaden weight loss operations and finalizing strategic joint ventures
- None.
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - August 28, 2024) - Investorideas.com, a go-to investing platform covering health and wellness and biotech stocks issues a snapshot looking at news and developments for the global GLP-1 receptor agonist market, featuring new player in the market, Integrated Ventures, Inc. (OTCQB: INTV).
Read the full article at Investorideas.com
https://www.investorideas.com/News/2024/biotech/08280GLP-1.asp
According to Research and Markets, The global GLP-1 receptor agonist market size is expanding at a CAGR of
Continued: "The strong product pipeline and formulation advancements are driving the market. In addition, novel innovative products are booming the market. In September 2019, Rybelsus, the first and only oral GLP-1 analog was approved by the U.S.FDA for improving the glycemic control in type-2 diabetes patients. It is a semaglutide-based product developed by Novo Nordisk, which is currently under review by European Medicines Agency (EMA) and Pharmaceuticals and Medical Devices Agency (PMDA). After receiving the approval, the market may witness significant growth over the forecast period."
"Furthermore, pharmaceutical companies are focusing on research collaborations for developing new GLP-1 products. For instance, in September 2018, Eli Lilly and Company entered into a license agreement with Chugai Pharmaceutical Co., Ltd for OWL833. OWL833 is Chugai's proprietary oral GLP-1 agonist candidate and as per the agreement Eli Lilly will obtain global commercialization and development rights."
Continued: "The Novo Nordisk A/S Ozempic segment dominated the market and accounted for a share of
Today, Integrated Ventures, Inc. (OTCQB: INTV) announced its strategic entry into the rapidly expanding health and wellness sector.
The initial phase of this transition will be led by the newly established subsidiary, MedWell USA, LLC, which will serve as a B2B Procurement Agent for a variety of pharmaceutical products, with a particular focus on the booming medical weight loss and GLP-1 markets.
MedWell USA will be focused on the development of innovative weight loss and wellness management solutions, targeting B2B clients such as medical offices, fitness facilities and wellness clinics. This approach is designed to meet emerging consumer demands and capitalize on the significant growth within the global health and wellness industry.
Steve Rubakh, CEO of Integrated Ventures, comments: "This strategic entry represents a significant evolution for our company. The health and wellness sector offers immense growth potential, and we are eager to bring unique and impactful solutions (B2B and B2C) to market that will meet the critical needs of consumers seeking to improve their health and well-being. According to UB Securities (*) forecast, the combined GLP-1 market for obesity and diabetes will reach
(*) https://www.ubs.com/global/en/investment-bank/in-focus/2024/glp-1-a-medication.html
In addition to launching MedWell USA, the Company is in the process of establishing two more subsidiaries aimed at broadening its weight loss related operations. Furthermore, the Company is finalizing strategic joint ventures that will enable INTV to quickly and effectively penetrate the lucrative health and wellness market.
Integrated Ventures is committed to driving shareholder value by seizing high-growth opportunities within the health and wellness sector. The Company will provide regular updates as it advances its strategic plans and achieves key milestones.
In May, Hims & Hers Health, Inc., the leading health and wellness platform, announced the addition of GLP-1 injections to its comprehensive weight loss portfolio, giving customers an affordable way to consistently access safe, high-quality weight loss treatment.
From the news: The company now offers access to GLP-1 injections in addition to weight management oral medication kits, so that customers can truly personalize their weight loss experience. Providing access to compounded GLP-1s means eligible customers can use medications with the same active ingredient as Ozempic® and Wegovy® without navigating the shortages and costs that are currently limiting access to the branded medications. Through a partnership with a leading US manufacturer of generic and 503B compounded injectable medications, Hims & Hers can help millions of Americans who have obesity and are looking for help safely managing their weight.
"The core of our business is to offer a truly personalized experience that customers can trust and rely on," said Andrew Dudum, CEO and co-founder of Hims & Hers. "We've leveraged our size and scale to secure access to one of the highest-quality supplies of compounded GLP-1 injections available today. We're passing that access and value along to our customers, who deserve the highest standard of clinical safety and efficacy to meet their goals, and we're doing it in a safe, affordable way that others can't deliver."
Continued: According to the US Food and Drug Administration (FDA), around
In June, Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced the presentation of preclinical data from a series of internally developed dual agonists of the amylin and calcitonin receptors at the 84th Scientific Sessions of the American Diabetes Association. The presentation highlighted the effects of treatment on body weight, food intake and metabolic profile in healthy rats and diet-induced obese (DIO) mice as compared to control cohorts treated with vehicle or the dual amylin and calcitonin receptor agonist cagrilintide. The studies were summarized in a poster presentation at the annual scientific conference of the American Diabetes Association, held in Orlando, Florida in June of this year,
From the news: The study results demonstrate that Viking's series of dual amylin and calcitonin receptor agonists (DACRAs) reduced food intake in lean rats in the period from 0 - 72 hours following a single subcutaneous dosing. At 72 hours following a single subcutaneous dose, Viking's novel compounds resulted in up to
Continued: In a DIO mouse model, treatment with Viking's series of co-agonists for 24 days resulted in body weight reductions that were comparable to those achieved in cagrilintide-treated animals. Additionally, improvements in key metabolic markers, including blood glucose levels, were observed in DIO mice treated with the company's compounds for the 24-day time period.
Looking at the future for the sector, Research and Markets notes, "The companies are currently aiming on geographical expansion for increasing the sales output. Novo Nordisk is expanding its business by investing in the manufacturing unit located in North Carolina. The company holds around
Continued: "The companies are also focusing on getting approval for other indications like obesity and major adverse cardiovascular events by authorities like the U.S.FDA, EMEA and others for the existing products to increase their life cycle."
Research and find more biotech stocks at Investorideas.com
https://www.investorideas.com/BIS/Stock_List.asp
Research health and wellness stocks at Investorideas.com
https://www.investorideas.com/LOHAS-investing/Stock_List.asp
About Investorideas.com
Investorideas.com is the go-to platform for big investing ideas. From breaking stock news to top-rated investing podcasts, we cover it all. Our original branded content includes podcasts such as Exploring Mining, Cleantech, Crypto Corner, Cannabis News, and the AI Eye. We also create free investor stock directories for sectors including mining, crypto, renewable energy, gaming, biotech, tech, sports and more.
Disclaimer/Disclosure: This news article featuring - Integrated Ventures, Inc. (OTCQB: INTV) is a paid for news release creation and dissemination on Investorideas.com. Our site does not make recommendations for purchases or sale of stocks, services or products. This is not investment opinion: Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services and prices on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ Global investors must adhere to regulations of each country. Privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Follow us on X @investorideas
Follow us on Facebook https://www.facebook.com/Investorideas
Follow us on YouTube https://www.youtube.com/c/Investorideas
Contact Investorideas.com
800-665-0411
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/221342
FAQ
What is Integrated Ventures, Inc. (INTV) new business focus?
What is the projected growth of the GLP-1 market for obesity and diabetes by 2029?
How is Hims & Hers Health expanding its weight loss portfolio?
What were the results of Viking Therapeutics' preclinical studies on dual agonists of amylin and calcitonin receptors?
